` DRREDDY (Dr Reddy's Laboratories Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

DRREDDY
vs
BSE Sensex 30

Over the past 12 months, DRREDDY has underperformed BSE Sensex 30, delivering a return of -10% compared to the BSE Sensex 30's 1% growth.

Stocks Performance
DRREDDY vs BSE Sensex 30

Loading
DRREDDY
BSE Sensex 30
Add Stock

Performance Gap
DRREDDY vs BSE Sensex 30

Loading
DRREDDY
BSE Sensex 30
Difference

Performance By Year
DRREDDY vs BSE Sensex 30

Loading
DRREDDY
BSE Sensex 30
Add Stock

Competitors Performance
Dr Reddy's Laboratories Ltd vs Peers

BSE Sensex 30
DRREDDY
LLY
JNJ
NOVO B
ROG
Add Stock

Dr Reddy's Laboratories Ltd
Glance View

Economic Moat
Narrow
Market Cap
923B INR
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.

DRREDDY Intrinsic Value
687.75 INR
Overvaluation 38%
Intrinsic Value
Price
Back to Top